Castration-resistant Prostate Cancer Clinical Trials

140 recruitingLast updated: July 11, 2026

There are 140 actively recruiting castration-resistant prostate cancer clinical trials across 51 countries. Studies span Phase 1, Phase 2, Phase 3, Early Phase 1, Not Applicable, Phase 4. Top locations include Houston, Texas, United States, New York, New York, United States, Nashville, Tennessee, United States. Updated daily from ClinicalTrials.gov.


Castration-resistant Prostate Cancer Trials at a Glance

140 actively recruiting trials for castration-resistant prostate cancer are listed on ClinicalTrialsFinder across 6 cities in 51 countries. The largest study group is Phase 1 with 68 trials, with the heaviest enrollment activity in Houston, New York, and Nashville. Lead sponsors running castration-resistant prostate cancer studies include Novartis Pharmaceuticals, AstraZeneca, and Astellas Pharma Global Development, Inc..

Browse castration-resistant prostate cancer trials by phase

Treatments under study

About Castration-resistant Prostate Cancer Clinical Trials

Looking for clinical trials for Castration-resistant Prostate Cancer? There are currently 19 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Castration-resistant Prostate Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Castration-resistant Prostate Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 140 trials

Recruiting
Phase 1

A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

Metastatic Castration-resistant Prostate Cancer (mCRPC)Metastatic Castration-resistant Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)+2 more
K36 Therapeutics, Inc.144 enrolled13 locationsNCT07103018
Recruiting
Phase 1

A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer

Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)Castration Resistant Metastatic Prostate Cancer+2 more
Aktis Oncology, Inc.138 enrolled3 locationsNCT07581184
Recruiting
Phase 1Phase 2

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

Metastatic Castration-resistant Prostate Cancer (mCRPC)Clear-Cell Renal-Cell Carcinoma (ccRCC)
Regeneron Pharmaceuticals345 enrolled24 locationsNCT03972657
Recruiting
Phase 1

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Metastatic Castration-resistant Prostate Cancer (mCRPC)Small Cell Lung Cancer ( SCLC )Follicular Lymphoma ( FL)
Pfizer453 enrolled83 locationsNCT03460977
Recruiting
Phase 3

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Metastatic Castration-resistant Prostate Cancer
Pfizer900 enrolled240 locationsNCT06629779
Recruiting
Phase 1Phase 2

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals205 enrolled14 locationsNCT07288359
Recruiting
Phase 2

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Prostate CancerMetastatic Castration-resistant Prostate CancerMetastatic Hormone Sensitive Prostate Cancer
Astellas Pharma Global Development, Inc.218 enrolled46 locationsNCT07005154
Recruiting
Phase 1

First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

Advanced Metastatic Castration-resistant Prostate CancerProstate Specific Membrane Antigen (PSMA) Expression
Bayer198 enrolled35 locationsNCT06217822
Recruiting
Phase 2

A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer
Hoffmann-La Roche100 enrolled39 locationsNCT07287150
Recruiting
Phase 4

A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

Non-metastatic Castration-resistant Prostate Cancer
Bayer50 enrolled25 locationsNCT05348876
Recruiting

Post Marketing Study on Pluvicto in Korea

Metastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals278 enrolled12 locationsNCT06514521
Recruiting
Phase 1

Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer (mCRPC)
Amgen40 enrolled5 locationsNCT07493512
Recruiting
Phase 2

Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC

Metastatic Castration-resistant Prostate Cancer
Yale University26 enrolled1 locationNCT06100705
Recruiting
Phase 3

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

Metastatic Castration-resistant Prostate Cancer
AstraZeneca670 enrolled104 locationsNCT07611110
Recruiting
Phase 2

Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Cancer
Swiss Cancer Institute162 enrolled13 locationsNCT06401980
Recruiting
Phase 3

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer
Celgene960 enrolled282 locationsNCT06764485
Recruiting
Phase 2

XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer
University of Utah32 enrolled1 locationNCT06568562
Recruiting
Phase 3

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer
BioNTech SE736 enrolled9 locationsNCT07365995
Recruiting
Phase 3

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer
Amgen750 enrolled136 locationsNCT07213674
Recruiting

An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea

Metastatic Hormone Sensitive Prostate CancerNon-metastatic Castration-resistant Prostate Cancer
Bayer600 enrolled1 locationNCT06334120